Abstract: During the 48-week treatment period, two patients in the ETV monotherapy group had viral breakthrough and the strains were confirmed to be of a variant associated with ETV resistance (
rtM204V+
rtL180M+
rtT184G), while one patient receiving LdT plus ADV had viral breakthrough and an LdT-associated resistance mutation (
rtM204I) was detected.